About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Medical Management of HER2+ eBC
Medical Management of HER2+ eBC
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
BC Side Effects & Survivorship: What Are the Most Common AI-Related Complaints?
By
2021 Virtual Best of Breast
FEATURING
Jennifer Klemp
,
Kristina Mirabeau-Beale
,
Kristin Rojas
,
Mayra Lima
By
2021 Virtual Best of Breast
FEATURING
Jennifer Klemp
,
Kristina Mirabeau-Beale
,
Kristin Rojas
,
Mayra Lima
80 views
January 21, 2021
0 Comments
Login to view comments.
Click here to Login
Medical Management of HER2+ eBC
09:13
Ilana Schlam
Extended Adjuvant HER2-Targeted Therapy With Neratinib for HER2+ EBC…
10:20
Sarah Donahue
Effective Management and Prevention of Neratinib-Induced Diarrhea in…
19:18
Nisha Unni
CONTROL Trial Data on HER2+ EBC: Dosing and Improving Tolerability o…
08:47
Moffitt Cancer Center
Improved Tolerability of Neratinib in Patients With HER2+ EBC: The C…
Feat.
H. Soliman
22:09
Yifan Tu
Bringing Diarrhea Under CONTROL: Adoption of Neratinib Dose Escalati…
30:01
Total Health
2021 Updates on Early Stage HER2+ Breast Cancer: Optimizing Adjuvant…
Feat.
C. Vogel
06:57
Total Health
2021 ASCO Updates on HER2-Directed TKIs in the eBC Adjuvant Setting:…
Feat.
J. Meisel,
H. Soliman
12:44
Total Health
Adjuvant Therapy for HER2+ EBC: Surveying Clinical Data
Feat.
J. Meisel,
H. Soliman
26:06
Total Health
Advances in Management of Early HER2+ BC: What Data Do We Have?
Feat.
T. Traina,
L. Carey
15:52
Erika Hamilton
Managing AEs Associated With HER2-Targeted Therapy in EBC
13:13
UCSF School of Medicine
ASCO 2021 Updates on Lisinopril or Carvedilol in Prevention of Trast…
Feat.
P. Munster
07:34
2021 Virtual Best of Breast
Postmenopausal Woman With Triple-Positive Breast Cancer: How to Appr…
Feat.
J. Klemp,
K. Mirabeau-Beale,
K. Rojas,
M. Lima
10:46
2021 Virtual Best of Breast
BC Side Effects & Survivorship: What Are the Most Common AI-Rela…
Feat.
J. Klemp,
K. Mirabeau-Beale,
K. Rojas,
M. Lima
07:26
Total Health
Expert Discussion on De-Escalation in Early Stage BC: Which Premenop…
Feat.
H. Rugo,
R. L. Mahtani
32:25
The Asian Oncology Society 1st Virtual International Conference
Residual Disease After Neoadjuvant Therapy - Updates on KATHERINE Tr…
Feat.
E. Perez
08:23
Nadia Harbeck
ASCO 2021 Updates on De-escalated Neoadjuvant Pertuzumab+Trastuzumab…
17:59
Total Health
The Current State of HER2+ EBC Treatment: Overview of NeoSPHERE, TRY…
Feat.
J. Meisel,
H. Soliman
07:57
Laura Kennedy
ExteNET Final OS Data for HER2+ EBC: How Effective Is Neratinib?
06:58
2020 ASCO Virtual Direct™ Highlights
Early Stage HER2+ BC: How Effective Is Adjuvant Neratinib?
Feat.
H. Rugo
07:43
Nancy Chan
Improved Tolerability of Neratinib in Patients With HER2+ EBC: The C…
36:13
Total Health
ESMO 2021 Updates on HER2+ EBC: Surveying the Recent Trials
Feat.
L. Schwartzberg
17:55
Marija Balic
Association Between Treatment Duration and OS in Early-Stage HER2+ B…
05:44
SABCS 2021 Conference Coverage on VuMedi
SABCS 2021 on CNS Metastases as a Site of First Recurrence in Adjuva…
Feat.
N. Lin